Going local – prevention conference hears about rings, douches, and soluble suppositories
Beyond Truvada – what is the future of PrEP?
Bictegravir matches dolutegravir in first-line treatment
Substantial gaps in PrEP care continuum for trans women in San Francisco
Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
Boston HIV clinic sees 90% reduction in infections in people being prescribed PrEP
PrEP providers and communicators should stop talking about ‘risk’
First large HIV prevention trial using antibodies will probably not be the last
